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Nanocapsules containing poly(D,L-lactide) shell and retinyl palmitate core have been prepared by the pre-
formed polymer interfacial deposition method. Dynamic light scattering measurements yielded an aver-
age hydrodynamic diameter of 220 nm and a polydispersity index of 0.12. Small-angle neutron scat-
tering experiments revealed the presence of two populations of nanocapsules of core diameters 192 and
65 nm. Freeze fracture transmission electron microscopy showed a polydisperse population of nanocap-
sules (NC), with a poly(D,L-lactide) shell thickness between 11 and 3 nm. For comparison purposes, nano-
emulsions (NE, no polymer) and nanospheres (NS, polymer matrix) were also prepared. Each type of
nanoparticles exhibited a different morphology (when examined by electron microscopy), in particular
NC showed deformability by capillary adhesion. All three types of nanoparticles successfully encapsu-
lated the poorly water-soluble molecules baicalein and benzophenone-3. The thermal behavior of the
various nanoparticles was different to a physical mixture of its individual components. Cytotoxicity
and phototoxicity assays, performed in human keratinocytes (HaCaT) and murine ﬁbroblasts (BALB/c
3T3), showed that the NC were only cytotoxic at high concentrations. In vitro release studies of benzophe-
none-3, by the dialysis bag method using NC and NS, showed a sustained release; however, permeation
studies using plastic surgery human abdominal skin in Franz diffusion cells showed that a higher amount
of benzophenone-3 from NC penetrated into the skin, most probably due to the deformable nature of
these nanoparticles.
 2012 Elsevier Inc. All rights reserved.1. Introduction Nanocapsules (NC) are nanoparticles containing either an oilyThe development of nanosized carriers or nanoparticles, such as
polymeric nanoparticles (including nanocapsules and nano-
spheres), solid lipid nanoparticles and liposomes, has received con-
siderable interest as a strategy for improving the dermal delivery
of therapeutically active molecules [1]. The small size of the
nanoparticulate carriers have been suggested as the basis why
such vehicles can enhance the skin permeation of the actives they
entrap, while at the same time protecting the actives from degra-
dation [1,2]. In addition to their small size, other physical proper-
ties of the nanoparticles, such as their charge and lipophilicity,
have been proposed as being important in determining the skin
permeation proﬁle of the compounds they contain [3].ll rights reserved.
de Ciência e Engenharia de
-000 São Cristóvão, SE, Brazil.or aqueous core surrounded by a polymeric shell, typically in com-
bination with a mixture of lipophilic and hydrophilic surfactants.
The main advantages of NC compared to nanospheres (NS, poly-
mer-only matrix systems) are their low polymer content and high
drug loading capacity [4]. The polymers used to prepare NC (and
indeed NS) for pharmaceutical use are typically biodegradable
and biocompatible and include poly(e-caprolactone) and poly(D,L-
lactide) [5]. In addition, NC contain a combination of hydrophilic
and lipophilic surfactants (generally in the concentration range
from 0.2 to 2 wt.%), necessary to increase their stability [6]. The
medium chain (caprylic/capric) triglyceride is widely used as the
oily phase of nanocapsules and is suitable for the encapsulation
of liposoluble drugs [7–9].
Previous studies in our group [10] have investigated the skin
permeation proﬁles of various nanocarriers loaded with nimesu-
lide as a model of hydrophobic drug: nanoemulsions (NE, prepared
in the absence of polymer), NS (polymer matrix only) and NC,
prepared from the medium chain triglyceride (Miglyol 810),
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Interestingly, while NC and NS formulations were found to be re-
tained in the stratum corneum, the corresponding NE were found
in the viable epidermis and deeper (dermis). Additionally, the NC
delivered the highest concentration of nimesulide into the deep
skin layers [10].
More recently, our group have reported studies on NC compris-
ing a poly(D,L-lactide) shell and containing retinyl palmitate in-
stead of the medium chain triglyceride, Miglyol 810 [11], which
is the most stable form of vitamin A – a very important molecule
in cellular differentiation and in the prevention of carcinogenesis
[12], and is widely employed in anti-aging formulations. Unexpect-
edly, the NC prepared with a retinyl palmitate and Span 60 core
and a poly(D,L-lactide) shell were found to be deformable, as as-
sessed by TEM in combination with negative staining [11]. Further-
more, permeation studies showed that these nanocapsules held
promise for the delivery of actives deep into the skin, as they per-
meated the skin uniformly (down to 30 lm), most probably due
to their deformable characteristics [11].
On the basis of these ﬁndings, the objective of the present work
was to bring a better structural understanding on similar NC, com-
prising retinyl palmitate (RP), poly(D,L-lactide) (PLA) and surfac-
tants (either Span 60 and Tween 80 or Pluronic 68). In addition,
these NC formulations are compared to equivalent nanospheres
(without RP) and nanoemulsions (i.e. without PLA but with surfac-
tants). In this contribution, we report comprehensive structural
studies of the nanoparticles using a combination of dynamic light
scattering, freeze fracture and negative staining transmission elec-
tron microscopy, differential scanning calorimetry and small-angle
neutron scattering (SANS). As far as we are aware, only one article
has previously reported SANS studies using contrast variation on
nanocapsules, which were prepared using Miglyol 812, poly(D,L-
lactide) and Pluronic F68 [9]. Signiﬁcantly, these SANS studies
yielded information on the thickness of the polymeric and surfac-
tant shell. In the present SANS study, the scattering length density
of the shell was contrast-matched to the solvent in order to yield
information on the size of the oil core of the NC. Following these
detailed structural studies, the potential of the nanoparticles to
act as drug carriers is established by evaluating their cytotoxicity,Table 1
Composition of nanoparticles.
Sample names Nanoparticle formulations
Organic phase (150 mL acetone
Polymer
(mg)
Retinyl
palmitate
(mg)
Mig
810
Samples with a ﬁnal volume of 100 mL
(after rotaevaporation)
NS 500 – –
NC 500 1500 –
NE – 1500 –
NSBZ3 500 – –
NCBZ3 500 1500 –
NEBZ3 – 1500 –
NSBAI 500 – –
NCBAI 500 1500 –
NEBAI – 1500 –
Volumes of 30 mL (after evaporation and before
dilutions with D2O for SANS analysis)
NCRP3SP 500 1500 –
NCMiSP 500 – 150
NCRP 500 1500 –
NCMi 500 – 150
NCRP2.5 500 1250 –
NCMi2.5 500 – 125
a With respect to their ﬁnal volumes.phototoxicity, and their ability to encapsulate two poorly-water
soluble model drugs, benzophenone-3 and baicalein. Baicalein
(5,6,7-trihydroxyﬂavone) was selected for this study as it possesses
free radical scavenging and antioxidant activity [13], as well as
anti-inﬂammatory effects and cellular activity enhancement in hu-
man gingival ﬁbroblasts [14]. Benzophenone-3 is a UV ﬁlter which
is found at concentrations up to 6% in skin formulations and is used
in cosmetic products to improve chemical stability [15]. Finally, in
order to demonstrate the suitability of these nanocapsules as skin
drug delivery systems, in vitro drug release and permeation stud-
ies, using plastic surgery human abdominal skin in Franz diffusion
cells, were also performed, and the results were correlated to the
physico-chemical characteristics.
2. Experimental procedures
2.1. Materials
Retinyl palmitate (RP) containing 1% butylhydroxytoluene
(BHT), poly(D,L-lactide) (PLA) of molecular weight of 75–120 kDa,
sorbitan monostearate (Span 60), sorbitan monooleate ethoxylate
(Tween 80), polyoxyethylene–polyoxypropylene block copolymer
(Pluronic F68), baicalein, buffer components, DMEM, neutral red,
hematoporphyrin and thiourea were purchased from Sigma–Al-
drich (St. Louis, MO, USA). Carbopol 940 was from BF Goodrich
(Cleeveland, OH, USA). Benzophenone-3 and capric/caprylic tri-
glyceride (Miglyol 810) were purchased from Delaware (Porto Ale-
gre, Brazil). Acetone, methanol, and ethanol were of analytical
grade and were obtained from Merck (Darmstadt, Germany). All
solvents and chemicals were used without further puriﬁcation.
All water used was previously puriﬁed and deionised by a Milli-
Q system (Millipore).
2.2. Nanoparticle preparation
Hereafter in the text, nanoparticles, nanocapsules, nanospheres
and nanoemulsions are referred to as NP, NC, NS and NE, respec-
tively. The formulations of NP are described in Table 1. The NC
were prepared by the pre-formed polymer interfacial deposition+ 50 mL ethanol) Aqueous phase (400 mL
water)
lyol
 (mg)
Span
60
(mg)
Benzophenone-
3 (mg)
Baicalein
(mg)
Pluronic
F68a (wt.%)
Tween
80a (wt.%)
300 – – 1.0 –
300 – – 1.0 –
300 – – 1.0 –
300 5.0 – 1.0 –
300 50.0 – 1.0 –
300 50.0 – 1.0 –
300 – 5.0 1.0 –
300 – 50.0 1.0 –
300 – 50.0 1.0 –
300 – – – 0.3
0 300 – – – 0.3
– – – – 0.3
0 – – – – 0.3
250 – – – 0.3
0 250 – – – 0.3
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retinyl palmitate, acetone and ethanol, was added to an aqueous
phase containing either Pluronic F68 or Tween 80 under magnetic
stirring at 37 C. Samples prepared with Tween 80 were found to
be more stable than those prepared using Pluronic F68 and were
therefore used for the small-angle neutron scattering (SANS) mea-
surements. All other NC reported in the present study were pre-
pared using Pluronic F68. It should be noted that neither the
nature of the surfactant, or even its absence, affected the size of
the NC immediately after their preparation, as assessed by dy-
namic light scattering (DLS) (Section 2.3). The organic solvents
were evaporated and the ﬁnal NC suspension concentrated under
reduced pressure using a rotary evaporator. NE and NS were pro-
duced by the same method as the NC but excluding the PLA poly-
mer and the oil, respectively.
When preparing baicalein and benzophenone-3-containing NC,
NS or NE, baicalein or benzophenone-3 was solubilized in the or-
ganic phase. When the model drugs are contained in the nanopar-
ticles, the letters BAI or BZ3, respectively, are added to the code
used to designate the type of formulation, such that retinyl palmi-
tate nanocapsules containing benzophenone-3 are denoted NCBZ3.
For the SANS experiments, samples were variously prepared
with Miglyol 810 in place of retinyl palmitate, in the absence or
presence of Span 60 and by using an oil:polymer weight ratio of
either 3:1 (as in all the other experiments) or to 2.5:1. For the SANS
samples therefore, the nomenclature NC was changed to NCRP3SP
(RP for retinyl palmitate, 3 for the oil:polymer weight ratio used
and SP to indicate the presence of Span 60, respectively), in order
to distinguish samples with Miglyol (Mi), with no Span 60 (for
e.g. NCRP3) or with an oil: polymer weight ratio of 2.5:1 instead
of 3:1 (e.g. NCRP2.5) (Section 2.4, Table 1).2.3. Measurement of apparent hydrodynamic particle size and zeta
potential
The apparent hydrodynamic size, size distribution, polydisper-
sity (expressed as a polydispersity index, PDI) and zeta potential
of the NP were determined using a Zetasizer Nano ZS (Malvern
Instruments, Worcestershire, UK). The measurements were made
by diluting 40-fold the NP prepared in an aqueous solution con-
taining 1 mM KCl at 25 C.Table 2
Relevant physical parameters used in the SANS experiments.
Materials Density
(g m3)
Scattering length
density, qa
Experimental
volume fractionb
Poly(D,L-lactide) 1.13 1.57  106 Å2 0.50%
Retinyl palmitate 0.98 2.98  107 Å2 1.75%
Miglyol 0.95 3.36  107 Å2 –
Span 60 1.00 3.14  107 Å2 0.34%
Tween 80 1.10 1.26  106 Å2 0.31%
Butylhydroxytoluene 1.05 4.51  107 Å2 0.03%
D2O 1.1 6.33  106 Å2 30.9% (of solvent)
H2O 1.0 5.60  107 Å2 69.1% (of solvent)
a Calculated from Eq. (1). Particularly for the polymer, the molecular weight used
was from monomer unit.
b These values are given for sample NCRP3SP as an example of typical volume
fractions.2.4. Structural studies
2.4.1. Transmission electron microscopy
The morphology of the NC was determined by freeze fracture
transmission electron microscopy (FFTEM). NC were frozen from
room temperature (ca. 22 C) as a thin ﬁlm between two copper
double-sided replica specimen holders (Bal-tec AG, BU0 12 055-
T) using slushed nitrogen (210 C). Samples were fractured at
150 C, shadowed at an angle of 45 with platinum/carbon and
coated with carbon in a Polaron E7500 freeze fracture unit
mounted on a Polaron E6000 series high vacuum station (Quorum
Technologies). The replicas were recovered by submerging the
specimen holder and replica in 2:1 v/v chloroform:methanol (Ana-
lar grade) for 2–3 min and then ﬂoating the replica off in distilled
water. Replicas were transferred with a platinum loop to copper
460 lines/inch hexagonal mesh grids (Agar Scientiﬁc Ltd.
G2750C). Images of the replicas were taken using a FEI Tecnai 12
TEM with Gatan Bioscan 760 digital camera (1024  1024 pixel
resolution).
NC, NS and NE were also examined by conventional TEM using
negative staining, employing a dried suspension of NP on a copper
grid with Formvar/carbon and dyed with 1 wt.% uranyl acetate
(Carl Zeiss CEM902, Okerkochen, Germany).2.4.2. Small-angle neutron scattering measurements
Small-angle neutron scattering (SANS) measurements were per-
formed on NC made in the absence and presence of Span 60, and
using either Miglyol 810 or retinyl palmitate as the oil phase in or-
der to assess their effect on NC structure. The composition of the
samples studied by SANS is given in Table 1, indicating the use of
either Miglyol 810 oil (Mi) or retinyl palmitate (RP) as the oil
phase, Span 60 or no Span 60 (the presence of which is indicated
by the letters ‘SP’) and the oil:polymer weight ratio used (either
3:1 or 2.5:1). It is important to state here that in all other experi-
ments reported in this paper, an oil:polymer weight ratio of 3:1
was used (in other words, elsewhere in this article the denomina-
tion ‘NC’ alone always refers to formulations with retinyl palmi-
tate, Span 60 and a 3:1 oil:polymer weight ratio, as described in
Section 2.2).
Samples were measured on the instrument D11 at the Institut
Laue Langevin (ILL) (Grenoble, France). Three conﬁgurations of
the instrument were used to cover a Q = 4p/ksin(h/2) range of
1.251  10 3 Å1 to 0.311 Å1, where Q is the modulus of the scat-
tering vector. The scattering from each sample was corrected for
electronic background, detector deadtime, scattering from the
empty cell and sample transmission. The intensity was converted
to differential scattering cross-sections in absolute units (cm1)
using the scattering from a water sample. Data reduction was per-
formed using the software Lamp [17,18].
The contrast factor in neutron scattering is given by the differ-
ence between the scattering length density of the sample (i.e. NC)
and the solvent (a mixture of H2O and D2O). The scattering length
density, q, of a sample is expressed by:
q ¼ 1
V
X
i
bi ¼ dNAM
X
i
bi ð1Þ
where d is the bulk density of the molecule, M its molecular weight
and bi the coherent neutron scattering length of nucleus i. The cal-
culated scattering length densities of the nanocapsules components
are given in Table 2, together with their density and experimental
volume fraction. It is assumed that the core of the NC is composed
of the oil, Span 60 and butylhydroxytoluene, giving an average q of
ca. 0.3  106 Å2.
In this paper, we present data where the composition of the sol-
vent (H2O/D2O mixture) was such that it matched the scattering
length density of the PLA shell (1.57  106 Å2) hence making it
(and, to a large extent, any Tween 80 micelles) ‘invisible’ to neu-
trons. Our results thus give information on the size of the NC oil
core.
2.4.3. SANS data modelling
Initial data evaluation was performed using the Guinier analysis
to achieve an estimate of the average radius of gyration. In dilute
Z. Teixeira et al. / Journal of Colloid and Interface Science 382 (2012) 36–47 39conditions, the Guinier approximation (as given by Kratky [19]) is
obeyed [19]:
IðQÞ ¼ Ið0Þ expðQ2R2g=3Þ ð2Þ
where I(0) is the coherent forward scattering intensity. By ﬁtting
the experimental data to Eq. (2), Rg can be assessed from the slope
of the linear part of a ln I(Q) vs Q2 plot, which is called a ‘‘Guinier
plot’’. Assuming a spherical shape, the radius of gyration is given by:
Rg ¼
ﬃﬃﬃ
3
5
r
R ð3Þ
where R is the radius of the sphere.
The data modelling program FISH was used to ﬁt the SANS data
[20]. Parameters are reﬁned from several starting points to ensure
that a global (rather than a local) minimum is found.
Data were ﬁtted using a model for polydisperse spheres, with a
size distribution following the Schultz model:
PðrÞ ¼ zþ 1
R
 zþ1
rz exp  zþ 1
R
R
 
1
Cðzþ 1Þ ð4Þ
where R is the average value of R, C(x) is the gamma function and z
is a measure of the width of the distribution. The polydispersity in-
dex returned by the ﬁt is given by r=R where r is expressed by:
r ¼ Rﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
zþ 1p ð5Þ
A pre-factor, referred to as the ‘scale’ factor, includes the exper-
imental parameters volume fraction and contrast. It is left to ﬂoat
and then the value returned by the ﬁt checked against its calcu-
lated value to conﬁrm consistency of the ﬁt. In this model, the
‘scale’ is given by /(Dq)2, where Dq represents the scattering
length density difference between the solute and the solvent and
/ is the volume fraction of the particles. Having calculated the
experimental contrast, this factor thus returned a value of the vol-
ume fraction, /, which was compared to the experimental one (an
error of ±25% was deemed acceptable). A ﬂat background is in-
cluded in the ﬁts to allow for residual incoherent background.
2.5. Differential scanning calorimetry
The thermal behavior of the NP was investigated by differential
scanning calorimetry (DSC) (Q10, TA Instruments). A drop of each
NP sample (NS, NC, NE and NCBZ3), at a concentration of
330 mg mL1 (produced by further concentrating the samples dur-
ing rotary evaporation), was added into an aluminum sample pan.
Each dropwas dried for 2 h in air. More drops of samplewere added
up to a ﬁnal weight (after air drying) between 14 mg and 16 mg.
After that, residual water (around 2 mg) was evaporated in a vac-
uum dynamic line. Pans were closed and the DSC measurements
were made under a 50 mL min1 ﬂow of N2 at a cooling rate of
5 C min1 from 25 C down to 3 C. The temperature of the sam-
ple was kept constant at 3 C for 5 min, and then increased from
3 C to 70 C at a heating rate of 5 C min1. The same method
was employed using around 15 mg of each individual ingredient
as well as a physical mixture in the same proportions of the nano-
particles. Each sample was measured in triplicate.
2.6. High performance liquid chromatography analysis
The amount of benzophenone-3 and baicalein in the NP after
extraction (Section 2.7) and in the various compartments in the
skin assay (Section 2.11) were evaluated by high performance li-
quid chromatography (HPLC) analysis using a Shimadzu HPLC
(detector SPD-M20A), C18 Varian column of dimensions of
4.6 mm  250 mm. The mobile phase consisted of methanol:aceticacid 1% (70:30 v/v). The mobile phase ﬂow-rate was 1.0 mL min1;
the column temperature was 25 C and the UV detection was at
289 nm and 320 nm for benzophenone-3 and baicalein, respec-
tively. The selectivity of the assay was conﬁrmed by the individual
analysis of the model molecule solution in methanol (i.e. baicalein
or benzophenone-3 free) in comparison to appropriately extracted
empty NP (Section 2.7), tape (Section 2.11) and skin (Section 2.11),
and the ﬂuid from the receptor compartment of the Franz diffusion
cells (Section 2.11). Linear response curves were obtained over
baicalein or benzophenone-3 concentrations in the range 0.1–
5.0 lg mL1 (r > 0.999).
2.7. Encapsulation efﬁciency
Quantiﬁcation of the total amount of baicalein and benzophe-
none-3 present in the various NP suspensions was determined by
HPLC (Section 2.6) after extraction of 100 lL of the NP suspensions
with 9.9 mL of methanol. The amount of free (i.e. unencapsulated)
drug in the NP suspension was determined by centrifugation/ﬁltra-
tion method in which 450 lL of the aqueous NP suspension was
centrifuged (10 min at 4000g) using a 100 kDa Millipore Microcon
membrane. NP were retained on the membrane ﬁlter while the
aqueous solution containing the free drug crossed the membrane
into the receptor phase. The amount of drug in the aqueous solu-
tion was established using HPLC analysis as described above. The
calculation of the encapsulation efﬁciency (EE) of the NP was
determined using
EE ¼ ½ðtotal drug free drugÞ=total drug  100 ð6Þ2.8. Cytotoxicity and phototoxicity assays
The BALB/c 3T3mouse embryo ﬁbroblast cell line, obtained from
the National Institute of Health (Baltimore, MD) and HaCaT human
keratinocyte cell line, kindly provided by Dr. Liudmila Kodach (Aca-
demic Medical Center, Amsterdam University), were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
100 U mL1 penicillin, 100 lg mL1 streptomycin and 10 wt.% fetal
bovine serum. Cells at 200 lL/well (1  105 cells mL1 BALB/c 3T3
and 7  104 HaCaT cells mL1) were seeded into 96-well plates
and incubated at 37 C in a humidiﬁed atmosphere containing 5%
CO2 for 24 h, after which they formed half-conﬂuent monolayers.
For each cell type, two plates were prepared: one plate was used
for the determination of cytotoxicity (i.e. in the absence of UVA),
and the other plate for the determination of phototoxicity (i.e. in
the presence of UVA). The cells were washed twice with phosphate
buffered saline (PBS), pH 7.4, and treated with different concentra-
tions of NC, NS and NE suspensions for 1 h at room temperature.
One plate was then exposed to a dose of 5 J cm2 UVA (i.e. photo-
toxicity test), at room temperature, for 50 min, whereas the other
plate was kept in the dark (i.e. cytotoxicity test), under the same
conditions. The UVA radiation source used was a 100 W Bellarium
S UVA lamp (Wolff System Technology Corporation; Kennesaw,
GA) that has the majority of its energy output between 300 nm
and 420 nm. The emitted dose was calculated using a UVA radiom-
eter photodetector (Cole-Parmer Instrument Co.). At the end of the
irradiation period, the cells in both plates were washed twice with
PBS and incubated in culture medium for 22 h. Cell viability was
then determined by the neutral red uptake (NRU) as previously de-
scribed [21,22].
For the prediction of phototoxicity potential, the BALB/c 3T3 cell
line was used and the concentration response curves concurrently
obtained in the presence (+UVA) and in the absence (UVA) of UVA
irradiation were compared, usually at the IC50 of each compound,
as described by Spielmann et al. [23] and Lasarow et al. [24]. Con-
trol cells were treated with PBS only. Thiourea and hematoporphy-
Table 3
Encapsulation efﬁciency (EE), drug loading, apparent hydrodynamic diameter (d), and
zeta potential of nanospheres (NS), retinyl palmitate nanocapsules (NC) and
nanoemulsions (NE) with and without baicalein (BAI) or benzophenone-3 (BZ3) for
samples fabricated on three different days.
Formulation EEa (%) Drug loading (%)
(mass of drug/
polymer  100)
d (nm) (PDI) Zeta
potential
(mV)
NCBZ3 99.8 10 227 ± 18 (0.12 ± 0.06) 17.0 ± 1.0
NSBZ3 99.7 1 123 ± 32 (0.04 ± 0.02) 27.5 ± 2.1
NEBZ3 99.9 10 210 ± 21 (0.17 ± 0.06) 25.3 ± 5.5
NCBAI 99.6 10 218 ± 22 (0.10 ± 0.06) 26.7 ± 6.6
NSBAI 95.6 1 134 ± 30 (0.04 ± 0.02) 11.1 ± 5.1
NS N/Ab N/A 125 ± 14 (0.08 ± 0.03) 8.7 ± 1.0
NC N/A N/A 220 ± 28 (0.12 ± 0.03) 14.9 ± 5.0
NE N/A N/A 212 ± 22 (0.10 ± 0.01) 17.1 ± 3.8
n = 3 for each experiment.
a Standard deviation, SD 6 0.1 for all samples.
b N/A = not applicable.
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Neither cytotoxicity nor phototoxicity were observed for thiourea
up to a concentration of 1400 lmol L1 (0.8 mg mL1), whereas
hematoporphyrin, tested up to a concentration of 8.5 lmol L1
(5.1 lg mL1), caused phototoxicity, with an IC50 value of
1.16 lmol L1 (0.7 lg mL1).
2.9. In vitro release of benzophenone-3
In vitro release behavior of benzophenone-3 from NP and free
compound were investigated by two-compartment dialysis meth-
od under sink conditions [25]. Appropriate amounts of the NP sus-
pension (to a ﬁnal benzophenone-3 concentration into the
membrane of 100 lg mL1) were added in PBS (0.1 mol L1, pH
7.4) and placed into dialysis membrane bags (Spectra/Por; MWCO:
3500). The bags were then placed in 500 mL of PBS containing 0.5%
of Tween 80 as the solution release media and kept at 37 C and a
constant 1000 rpm stirring. At predetermined time intervals, 3 mL
aliquots of the release media were withdrawn, ﬁltered and ana-
lyzed by the HPLC (Section 2.6). An aliquot with the same volume
of fresh PBS was replaced in the release medium. Each experiment
was performed in triplicate.
2.10. Skin permeation experiments
The Franz diffusion cells used had a nominal area of 2.01 cm2
and receiver compartment of 7.0 mL capacity. Human abdominal
skin was donated from plastic surgery. The subcutaneous lipid tis-
sue was removed immediately after the surgery and the skin was
stored frozen for up to 1 month before use. The epidermal side of
the skin was exposed to the donor chamber while the dermal side
was bathed with degassed PBS, containing 5 wt.% Tween 80 in the
receptor chamber. The receptor mediumwas kept at 37 C and was
constantly stirred. 5 mL of freshly prepared nanoparticle suspen-
sion, namely benzophenone-3-loaded retinyl palmitate NC
(NCBZ3) or benzophenone-3-loaded NS (NSBZ3), were incorpo-
rated in a 0.5 wt.% Carbopol 940 gel and placed in the donor com-
partment of the Franz diffusion cells non-occlusively for a total of
24 h. NSBZ3 samples were further concentrated (10 times) during
rotary evaporation in order to contain the same benzophenone-3
concentration as the other experiments. NS without benzophe-
none-3 (NS) were used as a control.
2.11. Skin extraction of benzophenone-3
At the end of the incubation time in the Franz diffusion cells, the
surface of the skin was washed three times with PBS and gently
dried with a cotton swab. The amount of benzophenone-3 in the
receptor chamberwas analyzedbyHPLC, as described in Section 2.4.
The benzophenone-3 in the stratum corneum (SC) was evaluated
after 20 times tape-stripping (6 cm) using Scotch Tape 750 (3 M,
St. Paul, MN). The benzophenone-3 was extracted from the tape
by depositing the tape in 7 mL of methanol at 40 C in ultrasonic
bath for 60 min and agitating in a vortex mixer for 4  30 s. The
remaining skin tissue was sliced into small pieces placed in another
vial with 5 mL of methanol and extracted by the same procedure.
The methanol was ﬁltered through a 0.45 lm nylon membrane
(Millex HN, Millipore) and analyzed by HPLC (Section 2.6) [26].
Each result was expressed as the mean ± standard deviation of
the data obtained from six Franz diffusion cells.
2.12. Statistics
The results of cytotoxicity and phototoxicity were expressed
relative to the viability obtained for the control cells, which was
denoted as 100%. Each result represents the mean ± standard devi-ation of three experiments run in triplicate (i.e. a total of n = 9).
Other results (i.e. encapsulation efﬁciency, drug release and skin
permeation) were expressed as the mean ± standard deviation.
Comparisons between the groups were performed using one way
analysis of variance (ANOVA) followed by Bonferroni’s modiﬁed
test. P < 0.05 was taken as signiﬁcant.3. Results and discussion
3.1. Nanoparticle preparation and structural characterization
Table 3 shows the apparent hydrodynamic diameter, zeta po-
tential and encapsulation efﬁciency of NC, NS and NE, which were
stable for at least 1 month at room temperature with respect to
their diameter and drug content (data not shown). Apparent
hydrodynamic diameters of all the NP measured by DLS were be-
low 250 nm, regardless of the absence or presence of either benzo-
phenone-3 or baicalein. In addition, each of the NP preparations
exhibited a polydispersity index of less than 0.2 and a monomodal
distribution. Independently of the presence or otherwise of drug,
the NC exhibited a larger apparent hydrodynamic size than the
corresponding NS. Signiﬁcantly, the size of the NP was very repro-
ducible, for example NC prepared on 3 different days exhibited a
mean apparent hydrodynamic diameter of 220 ± 28 nm and PDI
of 0.12 ± 0.05. All NP formulations exhibited a zeta potential which
was slightly negative, most probably due to the presence of hydro-
lyzed ester groups in the PLA shell. Surprisingly, the NE – which
contained no PLA – also possessed a negative zeta potential; the
reason for this is not clear at this time, although it may be due to
the hydrolysis of the RP into palmitic acid. In no case did the pres-
ence of drug in the NP affect the zeta potential of the NP, a result
which was as expected due to the hydrophobic nature of the drug.
Signiﬁcantly, all systems exhibited high levels of encapsulation of
the two poorly-water soluble molecules, with encapsulation efﬁ-
ciencies of at least 95.6% and up to 99.9% being achieved.
Fig. 1 shows NC morphologies observable via FFTEM. Although
there is quite a lot of variability in the overall size of the NC, there
is no obvious effect on morphology of the presence or absence of
the lipophilic surfactant, Span 60. In addition to determining NC
morphology, FFTEM has also been used to determine the shell
thickness of the NC [9,25,27]. The PLA wall is considered to be
the region delimited by the arrows, while the brighter region cor-
responds to the place where PLA polymer was removed during the
freeze fracture process (Fig. 1). Using FFTEM, Rübe et al. [9] deter-
mined a wall thickness of ca. 10 nm for Miglyol 812-containing NC
of 121 nm radius and PDI 0.13 (as determined by DLS). The same
Fig. 1. Morphological analysis of PLA nanocapsules by FFTEM made with retinyl palmitate as the oil core and Tween 80 in the aqueous phase: (a and b) with no Span 60; (c
and d) with Span 60. The arrows indicate the shell thicknesses: (a) 5.1 ± 0.7 nm, (b) 10.9 ± 1.2 nm, (c) 2.8 ± 0.4 nm and (d) 9.2 ± 1.4 nm. Overall diameters: (a) 123.8 ± 2.6 nm,
(b) 307.4 ± 6.2 nm, (c) 73.0 ± 2.1 nm and (d) 250.0 ± 9.1 nm. (Data estimated using Image Tool software; average and standard deviation of 10 measurements).
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shell to corroborate their FFTEM results. In the present study, the
wall thicknesses of the various NC studied varied with the overall
particle size, as estimated from the FFTEM pictures (Fig. 1), using
ImageTool program. For NC without Span 60, the wall thickness
was found to be between 5 nm (for an overall diameter of ca.
125 nm) and 11 nm (for an overall diameter of ca. 300 nm), and
for NC with Span 60 between 3 nm (for a diameter of ca. 75 nm)
and 9 nm (for a diameter of ca. 250 nm).
From the radius of the whole sphere (R) and the radius of the
core (r) measured by FFTEM (Fig. 1), the volume fractions of the
shell (Vfshell) may be calculated geometrically from:
VfShell ¼ 43pR
3  4
3
pr3
 
=
4
3
pR3 ð7ÞTable 4
Volume fractions of shells assessed geometrically from FFTEM (Eq. (8
without Span 60.
Sample Vfshell obtained geomet
from FFTEM picture (F
NC without Span 60
A 0.213 ± 0.029
B 0.200 ± 0.021
NC with Span 60
C 0.205 ± 0.029
D 0.201 ± 0.028We also suggest that a reasonable method to obtain the various
volume fractions in the NC structures is to consider the additive
property of volumes. In the present work, the volume of the shell
and core were considered as the volume of the polymer on one
hand and the volume of the oil and the lipophilic surfactant (Span
60) on the other. Thus, knowing the density of each component,
the theoretical volume fraction of the NC wall (Vfshell) may also
be determined by:
Vfshell ¼ mpolymer=qpolymer=ðmpolymer=qpolymer þmoil=qoil
þmSpan60=qSpan60Þ ð8Þ
wherem and q are the mass and the density of the polymer, surfac-
tant and oil, as indicated by the indices.)) and by additive method of volumes (Eq. (9)) for NC with and
rically
ig. 1)
Vfshell assessed by the additive
method of volumes
0.224
0.195
Fig. 2. Representative TEM images of (a) nanospheres (NS, polymer matrix with no oil); (b) nanoemulsions (NE, without polymer), (c) nanocapsules (NC, with oil core and
polymer shell).
Table 5
Core radii of the nanocapsules formulations obtained from SANS by either the Guinier
approximation or a ﬁt to a model consisting of two distributions of spheres, as well as
the total radii by use of DLS. SANS suggests a bimodal distribution, therefore two radii
are given, with the corresponding proportion of the total population in volume.
Guinier
(nm)
Spheres
(nm)
% volume of large
population
DLS
(nm)
NCRP3SP 106 56 85 27 71 104
NCMi3SP 116 51 92 29 62 93
NCRP3 130 55 114 48 61 126
NCMI3 121 58 98 32 66 100
NCRP2.5 112 56 95 32 65 100
NCMI2.5 114 47 91 29 65 92
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and (8), which shows a good correlation between the two methods.
Thus, the combination of Eqs. (7) and (8), when the overall size (R) is
known, gives the oil core radius (r) and seems to be a reasonable
approach to assess the shell thickness as: Shell thickness = R  r.
Overall, our results suggest that the shell thickness presents a
polydispersity related to its diameter distribution (Table 4), in
which larger particles also present larger shell thicknesses. For
example, considering overall diameters of 150 and 200 nm, the
shell thickness for NC with Span 60 (Vfshell = 0.19) using Eqs. (7)
and (8) are estimated to be 5 and 7 nm, respectively, which are
in agreement with the values estimated from FFTEM.
Fig. 2 shows the TEMmicrographs of the NP stained with uranyl
acetate. It is clear from Fig. 2 that the various types of NP exhibit
different morphologies. In agreement with earlier studies [11],
the NC appear to exhibit some degree of deformability (Fig. 2c), a
potentially very useful characteristic for the delivery of drugs
through the skin, suggesting a higher permeability of the carrier
than a rigid system. It is worth mentioning that the NC in particular
exhibited a high polydispersity in size from the pictures (Figs. 1
and 2c), which is in agreement with the SANS data analysis pre-
sented below.
SANS curves from six different formulations of NC (Table 5) are
shown in Fig. 3, where the scattering of the solvent was contrast-
matched to the PLA shell, so that only the NC core was ‘visible’
to the neutrons. Signiﬁcantly, the SANS data could not be ﬁtted
to a simple distribution of polydisperse spheres, even when the
polydispersity index was signiﬁcantly increased. Furthermore, it
was not possible either to describe the data by assuming an imper-
fect contrast-matching and taking into account some residual scat-
tering from the shell. However, by plotting the data as ln(I) vs Q in
the Guinier approximation, it was possible to distinguish two lin-
ear regions, from which two radii of gyration could be extracted
(over a Q-range such that Q 6 1/Rg).We therefore attempted to ﬁt the data with a model consisting
of two populations of spheres, which we found was suitable to de-
scribe the scattering data from all samples (Table 5 and Fig. 3).
Regardless of the composition of the NC, the proportion of the lar-
ger NC (by volume) varied between 60% and 70% of the total
population.
It is worth commenting, however, that the quality of the SANS
ﬁts obtained without allowing the scattering length densities to
ﬂoat (they were ﬁxed at the experimental values) varied across
the range of samples – probably due to some variability in the
quality of the contrast-matching of the polymer shell – and was
excellent for some of the samples and good for the rest. Further-
more, the values of the radii obtained bymodel ﬁtting were in good
agreement the sizes obtained by the Guinier analysis, although the
latter were higher, being skewed towards larger NC sizes. Con-
versely, the DLS data suggested a low level of sample polydisper-
sity (0.12) and a monomodal distribution. This was perhaps not
surprising as DLS is not as sensitive to smaller NC due to the fact
that the DLS measurements are weighted by the volume of the par-
ticles present, together with the fact that the large particle size NP
were by far the most common population. Signiﬁcantly however,
the larger of the two distributions of spheres show a good agree-
ment with the size determined by DLS measurements (Table 5).
As expected, light scattering measurements give slightly larger ra-
dii, because they measure a hydrodynamic radius, in addition to
the fact that, in this speciﬁc case, they include the polymeric shell
as well any associated water (while SANS in our conditions only
measure the oil core).
Thermal analysis is a useful technique to measure interactions
between encapsulated molecules and polymer inside NP, as well
as to describe the physical state or the presence of molecular dis-
persions of the encapsulated molecules [25]. Mu and Feng [28] pre-
viously studied poly(D,L-lactide-co-glycolide) (PLGA) NP coated by
a-tocopherol polyethyleneglycol succinate (TPGS) using DSC and
observed that the thermal behavior of the NP was very similar to
a physical mixture of the materials. PLGA-stabilized NP encapsu-
lating dexamethasone were also studied by DSC, and showed no
interaction between the dexamethasone and the stabilizing poly-
mer, most probably because of the low level of encapsulation of
the dexamethasone, in which crystals of dexamethasone were ob-
served macroscopically by sedimentation [29].
Fig. 4 shows the DSC analysis of the various NP prepared in the
present study, their individual components and physical mixtures
thereof. It is clear that the thermal behavior of the various NP is dif-
ferent from that of the physical mixtures, which is similar to the
superposition of the DSC traces obtained for the individual compo-
nents. When compared to the DSC obtained for the physical mix-
Fig. 3. Small-angle neutron scattering curves from PLA nanocapsules made with either retinyl palmitate or Miglyol 810 as the oil core, Span 60 as the lipophilic surfactant and
Tween 80 (0.3% (m/v)): NCRP3SP, NCMi3SP, NCRP3, NCMi3, NCRP2.5, NCMi2.5 (sample codes are given in Table 1). The solvent (H2O/D2O) is matched to the scattering length
density of PLA. The solid lines are ﬁts to two populations of spheres and the curves are multiplied by 2n with respect to the ﬁrst one (with n = 1, 2, . . .) for better clarity. Inset:
Guinier representation of the low-Q range of the data, highlighting two linear regions. Each curve is shifted upwards by 5 with respect to the preceding curve.
Z. Teixeira et al. / Journal of Colloid and Interface Science 382 (2012) 36–47 43tures, the DSC trace obtained for the NC exhibits an additional peak
at approximately 29 C. Interestingly, a similar melting endotherm
is also observed in the DSC trace obtained for the NS, which were
prepared in the absence of retinyl palmitate, although it is slightly
shifted to a higher temperature. In addition, the endotherms that
occur above 20 C appear at a lower temperature when in the form
of a NP than when the components are present in a physical mix-
ture, suggesting intermolecular interactions between the NP com-
ponents. Signiﬁcantly, the presence of the water-insoluble
molecule, benzophenone-3, did not signiﬁcantly affect the thermal0 20 40 60 0 20
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In order to predict the dermal safety of the NP formulations,
cytotoxicity and phototoxicity assays were conducted in two skin
cell lines, namely, the human keratinocyte cell line HaCaT and
the murine BALB/c 3T3 ﬁbroblasts. Fig. 5 shows the cytotoxicity
and phototoxicity activities of NC, NE and NS formulations. HaCaT
cells treated with NC show IC50 values of 897 lg L1 and
228 lmol L1 in the absence (UVA) and presence (+UVA) of UV
radiation, respectively. When tested in ﬁbroblasts, the NC exhibit
an IC50 of 90 lg L1 in the presence of UV radiation (+UVA), while
no IC50 could be measured in the absence (UVA) of radiation as
the concentration–response curve did not drop below 50% of the
control. NE exhibit phototoxicity in both cell lines, with IC50
(+UVA) values of 331 lg L1 and 200 lg L1 for keratinocytes and
ﬁbroblasts, respectively. In contrast, neither cytotoxicity nor
phototoxicity was observed for NS up to the highest concentrations
tested in either BALB/c 3T3 or HaCaT cells. Together, these results
suggest that the toxic potential of NC and NE is associated to UV
radiation. Thus, in order to conﬁrm the phototoxic potential of
these particles, the photoirritancy factor (PIF) was calculated as
previously described by Spielmann et al. [23] and Lasarow et al.
[24], using the 3T3 ﬁbroblasts as a model system.
The photoirritancy factor (PIF) can be calculated only if the con-
centration–response curves obtained in the presence and absence
of UV light drop below 50% of the controls, because only in these
cases can the two IC50 values (UVA and +UVA) be determined.
A phototoxic potential is then considered when the PIF value is
higher than 5. When a chemical is only cytotoxic in the presence
of UVA and not in its absence, it is not possible to determine the
PIF value. In these cases, the highest concentration that was tested
[Cmax(UVA)] is used to calculate the PIF; here a ‘‘PIF’’ value >1 pre-
dicts phototoxic potential. The modiﬁed ‘‘PIF’’ value can be calcu-
lated following [23]:
PIF ¼ CmaxðUVAÞ
IC50ðþUVAÞ ð9Þ
Thus, both NC and NE exhibit a potential for phototoxicity in
ﬁbroblasts, as predicted by PIF values larger than 1. If an IC50 can-
not be determined, in either the presence or absence of UVA, then
the PIF is assumed to be 1 and no phototoxic effects can be associ-
ated with the formulation [23]. Based on these assumptions, NS
can be considered safe for cosmetic applications, while NC present
phototoxic potential to BALB/c 3T3 ﬁbroblasts, suggesting that
exposure to sun should be avoided, as for other retinoids.
It is worth mentioning that it was not possible to determine the
phototoxic potential of the ‘‘free’’ retinyl palmitate because it is
highly lipophilic and therefore not water-soluble at the required
concentrations – even when using the maximum concentration
of solvent (dimethyl sulfoxide) that is allowed in the cytotoxicity
test.
3.3. In vitro release of benzophenone-3
Fig. 6 shows in vitro release proﬁles of free benzophenone-3
and benzophenone-3 encapsulated in NP under sink conditions,
evaluated using the dialysis method of Benita and Magenheim
[25].
The mechanism of drug release from polymeric nanoparticles
has been commonly described by Fickian and non-Fickian models,
which are characterized by the diffusion and relaxation of
polymer chains, respectively [30–33]. A combination of both
mechanisms is described by a semi-empirical formula by Ritger–
Peppas [32,33]:
ft ¼ atn ð10Þwhere ft is the drug fraction released at time t, a is a constant that
depends on the particle structure and geometrical shape and n an
exponent that incorporates the geometrical shape and the release
mechanism. For spherical particles, n varies from 0.43 (Fickian mod-
el) to 0.85 (non-Fickian model), whereas a value of n = 1 describes a
case-II release (diffusion through a plane sheet) [32,33]. Other
mathematical models commonly encountered are zero-order, ﬁrst
order, as well as Higuchi [34,35]. All of them were tested in our
samples and Table 6 presents the most meaningful ﬁts with the
associated correlation coefﬁcients.
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Table 6
Results of mathematical ﬁttings for the experimental in vitro drug release data.
Sample Model Functions R2
NCBZ3 Ritger–Peppas ft = 0.06t0.47 0.96
First-order ft = 0.59ex/33.0 + 0.60 0.99
NSBZ3 Ritger–Peppas ft = 0.07t0.47 0.96
First-order ft = 0.73ex/52.1 + 0.77 0.98
NEBZ3 Ritger–Peppas ft = 0.08t0.51 0.89
First-order ft = 0.99ex/27.6 + 0.90 0.99
BZ3 Ritger–Peppas ft = 0.015t1.06 0.98
First-order ft = 2.0ex/126  2.0 0.98
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Fig. 7. Distribution of benzophenone-3 carried by nanospheres (NSBZ3) and
nanocapsules (NCBZ3) in the stratum corneum removed by tape stripping and in
the remaining skin tissue (epidermis without stratum corneum plus dermis) after
24 h of skin permeation using Franz diffusion cells.
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for NC and NS is closer to a Fickian mechanism (n = 0.47). The same
ﬁt for NE gives n = 0.51 (however the ﬁt is less reliable with
R2 = 0.89). For free BZ3, n = 1.06 (R2 = 0.98), which clearly shows
a departure from both Fickian and non-Fickian mechanisms, prob-
ably due to the diffusion of the free BZ3 through the dialysis mem-
brane. The release kinetics of all samples are also in agreement
with a ﬁrst order exponential decay (R2  0.99), which is a model
commonly used to explain a release controlled by diffusion as well
[35].
A range of methods have been used to evaluate in vitro drug re-
lease, such as dialysis bag diffusion, bulk equilibrium reverse dial-
ysis sac, and centrifugal ultraﬁltration [25,36]. The methods by
diffusion through membranes by either dialysis bag or diffusion
cells – although the most commonly used – have been criticized
by some authors [25,36,37], who argue that they do not provide
perfect sink conditions, since the amount of free drug inside the
bag can reach saturation and the release can be dependent on
the diffusion through the membrane. Since the rate of a kinetic
process is determined by the slowest step, a release faster than
the diffusion through the membrane will not be evaluated cor-
rectly by this technique. In our results, it is quite possible that this
limitation occurred because of the slow release observed for the
free drug up to 24 h. After this period, the release of benzophe-
none-3 encapsulated in NC was seen to be slower than in the other
NP systems (NE and NS), probably because of the presence of a
polymeric wall of PLA, which is absent in the NE and which show
the fastest release. The presence of RP in the NC also resulted in a
slower release after 48 h than from the NS, which contain no oil
and have smaller diameters. Similar results were previously ob-
tained using a different system, in which xanthone encapsulatedin NE exhibited a faster release than in PLGA NC [38]. A systematic
study, using different types of dialysis membranes, as well as com-
paring different methods of release (dialysis and ultraﬁltration)
would probably bring more insight into the mechanisms involved,
but is beyond the scope of the present manuscript.
3.4. Skin permeation study: benzophenone-3 as a model drug
Fig. 7 shows the location in the isolated skin of benzophenone-3
delivered from NC and NS obtained after 24 h in Franz diffusion
cells. Benzophenone-3 was not detected in the receptor solution.
In our previous studies using the same NC, retinyl palmitate was
found in the receptor chamber in its detection limit, but it was
15-fold more concentrated than benzophenone-3 co-encapsulated
with retinyl palmitate used in the present study [11]. The NCBZ3
formulation gave a higher amount of benzophenone-3 in both
the stratum corneum and the skin without the stratum corneum
than the NSBZ3 formulation, in spite of the smaller size of NS.
These data corroborate the different morphologies observed in
Fig. 2, in which the NC was much more deformable than NS. In
our previous studies, the elasticity of this NC system was investi-
gated by extrusion through crossed polycarbonate membranes
with pore diameters of 50 nm [11]. Most of the particles permeated
through the smaller pore sizes of the membrane, whereas particles
with diameters above 300 nm were retained on the membranes. In
the same study, confocal laser scanning microscopy showed that
the NC permeated uniformly down to a considerable depth
(30 lm) through the corneocyte layer [11]. The deformability ob-
served by TEM was attributed to capillary adhesion during the dry-
ing process [11].
Most polymeric NS do not permeate into the skin, as appears
from a review of recent literature. In a study on poly(e-caprolac-
tone) NS, confocal laser scanning microscopy (CLSM) images re-
vealed that nile red encapsulated in the NS (of average diameter
250 nm) permeated much more deeply in the skin when compared
to a control of nile red solution in propylene glycol [39]. In a sub-
sequent study by the same group, the skin distribution of ﬂuores-
cent polystyrene NS of 20 and 200 nm was determined and their
preferential distribution in follicular openings observed by CLSM;
the results suggested that neither size of polymeric NS permeated
the skin [40]. Rather, the authors concluded that the higher dye
permeation in their ﬁrst study [39] was probably related to a
46 Z. Teixeira et al. / Journal of Colloid and Interface Science 382 (2012) 36–47homogeneous release of the dye and not connected with the per-
meation of the carrier as initially suggested [40]. In another study
using single stained PLGA nanoparticles [41], the transdermal
delivery of ﬂufenamic acid was seen to be improved by up to
50% more drug into deep skin layers (for incubation times higher
than 12 h) in comparison to the free drug formulations). It was
shown that the NS had probably a pH effect due to its acidiﬁcation
by degradation of the polyester, which inﬂuenced the ionization
state of the drug, thus improving the concentration gradient from
the stratum corneum to the dermal side as evaluated by HPLC
(since ﬂufenanic acid did not present ﬂuorescence and thus could
not be evaluated by CLSM). The functionalized PLGA was used for
CLSM studies. However, at least for short periods of incubation
(30 min), the particles remained at the surface of the skin [41].
The release, accumulation and penetration after dermal adminis-
tration of NS made of ﬂuorescein-functionalized PLGA (encapsulat-
ing Texas red dye as a drug model) were studied by multiphoton
microscopy, using a dually-ﬂuorescence labelled model system in
excised human skin. The technique enabled a clear discrimination
between particle-bound and released drug, thus showing that only
the drug permeated to deep skin layers, not the NS [42]. Overall
therefore NS generally do not seem to penetrate deep into the skin.
To our knowledge, only one report in the literature makes a
comparative study of NC, NS and NE [10]. The polymeric systems
reported were nimesulide-loaded polycaprolactone NS, nimesu-
lide-loaded polycaprolactone NC containing Miglyol 810 and
nimesulide-loaded NE containing Miglyol 810, exhibiting average
hydrodynamic diameters of 202 nm, 277 nm and 252 nm,
respectively [10]. The authors observed that the deepest perme-
ation of the drug was obtained with the NC and that the NP (both
NC and NS) were retained in the stratum corneum. In the case of
NE, no drug was detected in the stratum corneum layer. This obser-
vation was attributed to a higher afﬁnity of the polymer for the
skin layers [10]. In the present study, a greater permeability of drug
was also observed for drug encapsulated in NC than for drug en-
trapped in NS.
Besides the surface characteristics and the size of nanocarriers
being crucial for their permeation into the skin, the deformability
of the NP carrier should also be taken into consideration [43–45].
The skin pores, which would provide a uniform permeation
through the skin (due to their high number and uniform distribu-
tion in comparison to the follicular openings), present very small
sizes (<10 nm). However, these pores are deformable and can be
expanded up to 40 nm and much larger particles have been
shown to permeate the skin through transepidermal pressure
(non-occlusively) [43]. In the review mentioned, the authors sug-
gested that ‘hard’ particles (i.e. non-deformable, for example inor-
ganic ones), even smaller than 20 nm, as well as ‘soft’ (deformable)
ones larger than 200 nm, are not attractive for transcutaneous drug
delivery and only of interest if hair follicles are targeted [43]. The
average diameter of the deformable NP used in the present work
are around this threshold (200 nm), therefore some particles
could be expected to permeate into the skin. Fig. 7 indeed showed
that drug-loaded into NC better permeate into the skin than the
drug contained in the smaller – but non-deformable – NS. This
observation agrees with our previous study, which showed that
nile blue functionalized-RP NC were found into deep skin layers
by CLSM [11].
One example of deformable NP are polymersomes of poly(cap-
rolactone)–poly(ethylene glycol)–poly(caprolactone), of average
diameter 122 nm and wall thickness 25 nm, which have been
shown to be ﬂexible by AFM and TEMmeasurements [44]. Fluores-
cently-labelled polymersomes were found to permeate deeply into
the skin layers, around a depth of 50 lm after 8 h (probably at the
interface between the stratum granulosum and stratum basal) and
around 60 lm after 24 h. Thus, it is in agreement with our previousstudy, in which a permeation around 30 lm was observed after
4 h, which was suggested to be a consequence of the ﬂexibility of
the RP NC [11]. Conversely, iron NP, as an example of ‘hard’ NP,
smaller than 10 nm, have been shown to penetrate the skin down
to the deepest layers of the stratum corneum, although not as far as
the uppermost strata of the viable epidermis. The suggested mech-
anisms of penetration were through the lipid matrix and follicular
route [46]. However it is clear that the skin permeation of hard NP
is not always easily predictable. For example, quantum dots with
diameters around 4 nm have been reported not to permeate excise
human skin [47], while on the other hand, gold NP of 15, 102 and
192 nm have been found in the deep layers of rat skin by TEM and
energy dispersive X ray spectroscopy (EDS) using Franz diffusion
cells. In this latter study, the larger particles were mainly observed
in the epidermis and dermis, while the nanoparticles of 15 nm
were found deeper into the skin. Surprisingly, the amount of
102 nm gold NP that permeated across the skin (into receptor
chamber) after 4 h was even higher than the NP of 15 nm size [48].
In a recent study, the biological barriers to the permeation of NC
were suggested as a function of their deformability [44]. The formu-
lations consisted of poly(e-caprolactone) and a mixture of capric/
caprylic triglyceride and octyl methoxycinnamate, denominated
NC, as well as the same composition but with added Span 60,
denominated lipid core nanocapsules (LNC), both stabilized with
Tween 80. The NP showed a monomodal diameter distribution of
200 nm, measured by DLS, and a slightly negative zeta potential.
The Young’s modulus values, determined by atomic force micros-
copy (AFM) in indentation mode, were 0.54 (LNC) and 0.36 MPa
(NC), considering a conical geometry, and 0.24 (LNC) and 0.17
(NC) MPa, considering a spherical geometry. The authors observed
hysteresis when comparing force curves during the approach and
retraction of the indenter, showing some viscoelasticity, which is
expected of a ﬂexible system. Thus, the author suggested that the
mechanical properties of the LNC (‘softness’ or deformability) could
be tuned by using Span 60 dispersed in the oily phase [45].
In the present work, we have conﬁrmed that NC are not only
capable of delivering retinyl palmitate into the skin but can also
co-encapsulate drug molecules, such as benzophenone-3, allowing
their delivery deep into the skin. Overall, actives encapsulated in
NC exhibited deeper skin permeation and higher levels of retention
in the skin (Fig. 7) than the same actives contained in NS. This may
be in part attributed to the ﬂexibility of the NC, as suggested by the
different morphologies observed by TEM (Fig. 2). In this context,
the fact that only the NC showed deformability appears to be
key, as this seems to enable a homogeneous delivery of the bioac-
tives or possibly a deeper skin permeation of the NC themselves.4. Conclusions
Nanocapsules (NC) containing a poly(D,L-lactide) shell and a ret-
inyl palmitate core were prepared by pre-formed polymer interfa-
cial deposition method and compared to the equivalent
nanospheres (NS, polymer matrix) and nanoemulsions (NE, with-
out polymer). The NC were larger than the NS (220 nm against
125 nm diameter, respectively) and exhibited a morphology differ-
ent from the one observed for the NS and NE. FFTEM images re-
vealed a poly(D,L-lactide) shell thickness between 11 and 3 nm,
varying with the overall size of the nanocapsules. Small-angle neu-
tron scattering studies in shell-matched conditions (thus high-
lighting only the oil core) revealed a distribution of two
populations, the larger one (60–70% in volume) being 192 nm
diameter and the smaller one 66 nm (taken as averages of
slightly varying formulations). Ratios and sizes varied slightly with
the oil:polymer ratio and the amount of lipophilic surfactant Span
60. A different thermal behavior was observed for the nanoparti-
Z. Teixeira et al. / Journal of Colloid and Interface Science 382 (2012) 36–47 47cles, when compared to the mixtures of the constituting ingredi-
ents. The comparison of formulations with and without Span 60
suggested that this surfactant is most probably solubilized in the
oil core, since the peak of the oil melting point was broader in its
absence. The NC were able to encapsulate more than 99% of either
baicalein or benzophenone-3. As the NC were only phototoxic at
high concentrations, they were therefore deemed to be suitable
as transdermal delivery vehicles. Furthermore, NC containing a
model drug molecule, benzophenone-3, were able to deliver it into
the skin and in particular reach the viable epidermis.
Thus, the main ﬁnding of this work is that in spite of the larger
size of the NC, as compared to NS, their apparent ﬂexibility seem to
enable them to penetrate through the horny layer, as their defor-
mability may inﬂuence skin-particle afﬁnity.
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